Alcohol Consumption and Hepatitis C Virus (HCV) RNA Levels in HIV/HCV Coinfected Patients.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
21 04 2021
Historique:
received: 31 01 2021
revised: 07 04 2021
accepted: 19 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 18 8 2021
Statut: epublish

Résumé

The impact of Hepatitis C virus (HCV) RNA levels on the evolution of chronic HCV infection-related liver damage is controversial. Heavy alcohol use is believed to have a deleterious impact on the course of HCV disease, but current knowledge about the possible effect of alcohol use on HCV RNA levels in HIV/HCV coinfected patients is limited. We examined 107 HIV/HCV-infected individuals with current or past unhealthy alcohol use to assess the association between alcohol consumption (any drinking vs. abstinent) and HCV RNA levels. Participants were 75% male, with a mean age of 43 years, and 63% were on antiretroviral therapy. Mean (SD) log HIV RNA was 3.1 (1.4) and mean (SD) log HCV RNA was 6.1 (0.8). Past-month alcohol use was present in 38% of participants. In a multivariable linear regression analysis we found no significant differences in mean log HCV RNA levels between those reporting alcohol use and those who were abstinent [β (95%CI): -0.04 (-0.34, 0.26), We did not detect significant associations between alcohol use and HCV RNA levels among HIV/HCV coinfected patients.

Sections du résumé

BACKGROUND
The impact of Hepatitis C virus (HCV) RNA levels on the evolution of chronic HCV infection-related liver damage is controversial. Heavy alcohol use is believed to have a deleterious impact on the course of HCV disease, but current knowledge about the possible effect of alcohol use on HCV RNA levels in HIV/HCV coinfected patients is limited.
METHODS
We examined 107 HIV/HCV-infected individuals with current or past unhealthy alcohol use to assess the association between alcohol consumption (any drinking vs. abstinent) and HCV RNA levels.
RESULTS
Participants were 75% male, with a mean age of 43 years, and 63% were on antiretroviral therapy. Mean (SD) log HIV RNA was 3.1 (1.4) and mean (SD) log HCV RNA was 6.1 (0.8). Past-month alcohol use was present in 38% of participants. In a multivariable linear regression analysis we found no significant differences in mean log HCV RNA levels between those reporting alcohol use and those who were abstinent [β (95%CI): -0.04 (-0.34, 0.26),
CONCLUSIONS
We did not detect significant associations between alcohol use and HCV RNA levels among HIV/HCV coinfected patients.

Identifiants

pubmed: 33919027
pii: v13050716
doi: 10.3390/v13050716
pmc: PMC8142976
pii:
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAAA NIH HHS
ID : U24 AA020778
Pays : United States
Organisme : NIAAA NIH HHS
ID : U24 AA020779
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI042853
Pays : United States
Organisme : NIAAA NIH HHS
ID : K24 AA015674
Pays : United States

Références

Drug Alcohol Depend. 2006 May 20;82(3):231-7
pubmed: 16256278
Alcohol Clin Exp Res. 2006 Apr;30(4):709-19
pubmed: 16573590
AIDS. 2012 Jul 31;26(12):1509-16
pubmed: 22555162
Alcohol Clin Exp Res. 2006 Sep;30(9):1520-6
pubmed: 16930214
AIDS. 2012 Sep 24;26(15):1917-26
pubmed: 22781222
AIDS Care. 2007 Sep;19(8):1039-47
pubmed: 17852002
Lancet. 2011 Apr 2;377(9772):1198-209
pubmed: 21459211
J Hepatol. 2012 Feb;56(2):334-40
pubmed: 21756854
Res Virol. 1997 Jul-Aug;148(4):267-71
pubmed: 9272577
Alcohol Alcohol. 2000 May-Jun;35(3):296-301
pubmed: 10869251
JAMA. 2015 Mar 24-31;313(12):1223-31
pubmed: 25706092
J Community Health. 2008 Jun;33(3):126-33
pubmed: 18165889
AIDS. 2008 Jan 30;22(3):415-20
pubmed: 18195568
Drug Alcohol Depend. 2016 Dec 01;169:101-109
pubmed: 27810652
AIDS. 2000 Jan 28;14(2):212
pubmed: 10708298
Semin Liver Dis. 2009 May;29(2):188-99
pubmed: 19387918
AIDS Care. 2000 Jun;12(3):255-66
pubmed: 10928201
Drug Alcohol Depend. 1996 Sep;42(1):49-54
pubmed: 8889403
Curr HIV/AIDS Rep. 2010 Nov;7(4):226-33
pubmed: 20814765
Alcohol Clin Exp Res. 2004 Apr;28(4):572-7
pubmed: 15100608
J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):171-8
pubmed: 22820808
Hepatology. 2005 Dec;42(6):1446-52
pubmed: 16317675
Med Clin (Barc). 2012 May 19;138(14):627-32
pubmed: 21696783
PLoS One. 2011;6(11):e27436
pubmed: 22087316
Hepatology. 1999 Mar;29(3):904-7
pubmed: 10051496
N Engl J Med. 2018 Sep 27;379(13):1251-1261
pubmed: 30257164
AIDS. 2013 Oct 23;27(16):2559-66
pubmed: 23770493
Hepatology. 2009 Apr;49(4):1335-74
pubmed: 19330875
J Hepatol. 2001 May;34(5):730-9
pubmed: 11434620
Am J Epidemiol. 1997 Dec 1;146(11):975-81
pubmed: 9400340
Hepatology. 1998 Jun;27(6):1717-22
pubmed: 9620348
Clin Infect Dis. 2005 Jul 1;41 Suppl 1:S105-9
pubmed: 16265607
Semin Liver Dis. 2004;24 Suppl 2:3-8
pubmed: 15346240
Nature. 2009 Oct 8;461(7265):798-801
pubmed: 19759533
J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):194-9
pubmed: 17667330
Antivir Ther. 2003 Oct;8(5):365-72
pubmed: 14640382
Gut. 2005 Oct;54(10):1468-72
pubmed: 16162952
J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):180-202
pubmed: 19668086
HIV Med. 2008 Apr;9(4):196-202
pubmed: 18366443
Med Care. 2005 Jun;43(6):574-85
pubmed: 15908852
J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):411-7
pubmed: 17099312
Clin Gastroenterol Hepatol. 2005 Nov;3(11):1150-9
pubmed: 16271348
World J Gastroenterol. 2007 May 7;13(17):2436-41
pubmed: 17552026
J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):471-6
pubmed: 16652056
Dig Dis Sci. 2001 Aug;46(8):1677-83
pubmed: 11508667

Auteurs

Daniel Fuster (D)

Department of Internal Medicine, Addiction Unit Hospital Universitari Germans Trias i Pujol, Department of Medicine, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.

David Nunes (D)

Section of Gastroenterology, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA 02118, USA.

Debbie M Cheng (DM)

Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA 02118, USA.
Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA.

Richard Saitz (R)

Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA 02118, USA.
Department of Community Health Sciences, Boston University School of Public Health, Boston, MA 02118, USA.
Grayken Center on Addiction, Boston Medical Center, Boston, MA 02118, USA.

Jeffrey H Samet (JH)

Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA 02118, USA.
Department of Community Health Sciences, Boston University School of Public Health, Boston, MA 02118, USA.
Grayken Center on Addiction, Boston Medical Center, Boston, MA 02118, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH